错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

CDK9-55 guides the anaphase-promoting complex/cyclosome (APC/C) in choosing the DNA repair pathway choice

  • Luigi Alfano,
  • Carmelina Antonella Iannuzzi,
  • Daniela Barone,
  • Iris Maria Forte,
  • Maria Carmen Ragosta,
  • Maria Cuomo,
  • Giulio Mazzarotti,
  • Milena Dell’Aquila,
  • Angela Altieri,
  • Antonella Caporaso,
  • Cristin Roma,
  • Laura Marra,
  • Silvia Boffo,
  • Paola Indovina,
  • Michelino De Laurentiis,
  • Antonio Giordano

摘要

DNA double-strand breaks (DSBs) contribute to genome instability, a key feature of cancer. DSBs are mainly repaired by homologous recombination (HR) and non-homologous end-joining (NHEJ). We investigated the role of an isoform of the multifunctional cyclin-dependent kinase 9, CDK9-55, in DNA repair, by generating CDK9-55-knockout HeLa clones (through CRISPR-Cas9), which showed potential HR dysfunction. A phosphoproteomic screening in these clones treated with camptothecin revealed that CDC23 (cell division cycle 23), a component of the E3-ubiquitin ligase APC/C (anaphase-promoting complex/cyclosome), is a new substrate of CDK9-55, with S588 being its putative phosphorylation site. Mutated non-phosphorylatable CDC23(S588A) affected the repair pathway choice by impairing HR and favouring error-prone NHEJ. This CDK9 role should be considered when designing CDK-inhibitor-based cancer therapies.